Download PDF
Geburtshilfe Frauenheilkd 2010; 70(2): 104-111
DOI: 10.1055/s-0029-1240822
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Kontrazeption in der Perimenopause

Contraception During PerimenopauseD. Foth1 , G. Göretzlehner2
  • 1Uniklinik Köln, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Köln
  • 2Parkstraße 11, 18057 Rostock
Further Information

Publication History

eingereicht 4.5.2009 revidiert 18.11.2009

akzeptiert 19.11.2009

Publication Date:
12 February 2010 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

In der Perimenopause, der unmittelbaren Zeit vor der Menopause und in dem 1 Jahr danach, ist die Reproduktion noch nicht erloschen. Ovulationen können ohne Vorankündigungen auftreten und daher ist eine effektive Kontrazeption erforderlich, besonders wenn eine Schwangerschaft nicht mehr erwünscht ist. Keine kontrazeptive Methode ist nur allein durch das Alter kontraindiziert. Daher können die verschiedensten kontrazeptiven Methoden perimenopausalen Frauen empfohlen werden: orale hormonale Kontrazeptiva mit niedriger Ethinylestradioldosis, Gestagene (z. B. estrogenfreie orale hormonale Kontrazeptiva, injizierbare Depotgestagene, Hormonimplantate), das Intrauterinsystem mit Levonorgestrel, natürliche Estrogene in Kombination mit einem Gestagen, kupferhaltige IUP, Barrieremethoden oder die Tubensterilisation. Allerdings sollten die Frauen eine genaue individuelle Beratung über die Risiken und Nutzen der jeweiligen kontrazeptiven Methode erhalten. Die oralen hormonalen Kontrazeptiva mit Ethinylestradiol-Gestagen-Kombinationen sind eine sichere Option für alle gesunden Nichtraucherinnen mit normalem Blutdruck und fehlenden anderen Kontraindikationen bis zu 1 oder 2 Jahren nach der Menopause, da die Anwendung mit zahlreichen gesundheitlichen Vorteilen verbunden ist. Gestagenpräparate kommen für Frauen mit Kontraindikationen gegen Estrogene infrage. Die levonorgestrelhaltige Hormonspirale (Mirena®) ist die effektivste Methode zur Kontrazeption in der Perimenopause, auch für Frauen mit Zyklusstörungen. Für Zigarettenraucherinnen sind alle Estrogenkombinationspräparate ab dem 35. Lebensjahr aufgrund eines erhöhten kardiovaskulären Risikos absolut kontraindiziert.

Abstract

During perimenopause, the time immediately prior to and the first year after the last menstrual period, female reproductive capacity is low, but pregnancy is still possible. Ovulation may occur without warning and effective contraception is still necessary if pregnancy is not desired. There is no contraceptive method that is contraindicated due to age. Various contraceptive options may be offered to perimenopausal women, including oral contraceptives with low dosages of ethinylestradiol, vaginal ring, progestin pills, injectables, implants, intrauterine system with levonorgestrel, natural estrogen (estradiol) in combination with a progestin, intrauterine devices, barrier methods and tubal ligations. However, women need to receive accurate individual advice about the risks and benefits of each contraceptive method. Oral hormonal contraceptives are a safe option for healthy, normotonic non-smokers without any contraindications up until one or two years beyond menopause. In addition to the effective contraception, non-contraceptive benefits such as the treatment of bleeding disorders or dysmenorrhea play an important role. For women with contraindications against estrogens progestin-only methods (pills, injectables, implants) offer possible choices. The intrauterine system (IUS) with levonorgestrel remains the most effective contraceptive method, even in women with bleeding disorders. For smokers all estrogen-progestin combinations are contraindicated because of the known increased risk for cardiovascular disease.

Schlüsselwörter

Kontrazeption - Perimenopause

Key words

perimenopause - contraception

Literatur

  • 1 Hardy R, Kuh D. Reproductive characteristics and the age at inception of the perimenopause in a British national cohort.  Am J Epidemiol. 1999;  149 612-620
    PubMedGoogle Scholar
  • 2 Klein N A, Soules M R. Endocrine changes of the perimenopause.  Clin Obstet Gynecol. 1998;  41 912-920
    CrossrefPubMedGoogle Scholar
  • 3 Bastian L A, Smith C M, Nanda K. Is this woman perimenopausal?.  JAMA. 2003;  289 895-902
    CrossrefPubMedGoogle Scholar
  • 4 Taffe J R, Dennerstein L. Menstrual patterns leading to the final menstrual period.  Menopause. 2002;  9 32-40
    CrossrefPubMedGoogle Scholar
  • 5 Soules M R, Sherman S, Parrott E et al. Stages of Reproductive Aging Workshop (STRAW).  Fertil Steril. 2001;  76 874-878
    CrossrefPubMedGoogle Scholar
  • 6 Burger H G, Hale G E, Dennerstein L et al. Cycle and hormone changes during perimenopause: the key role of ovarian function.  Menopause. 2008;  15 603-612
    CrossrefPubMedGoogle Scholar
  • 7 van Disseldorp J, Faddy M J, Themmen A P et al. Relationship of serum antimüllerian hormone concentration to age at menopause.  J Clin Endocrinol Metab. 2008;  93 2129-2134
    CrossrefPubMedGoogle Scholar
  • 8 Sowers M R, Eyvazzadeh A D, McConnell D et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition.  J Clin Endocrinol Metab. 2008;  93 3478-3483
    CrossrefPubMedGoogle Scholar
  • 9 Gray R H. Biological and social interactions in the determination of late fertility.  J Biosoc Sci Suppl. 1979;  6 97-115
    PubMedGoogle Scholar
  • 10 Kuhl H, Wiegratz I. Klimakterium, Postmenopause, Hormonsubstitution. 4. Aufl. Bremen; UNI-MED 2008
    PubMedGoogle Scholar
  • 11 Ulrich R E. Kontrazeption in Europa. http://www.berlin-institut.org/online-handbuchdemografie/bevoelkerungsdynamik/faktoren/fertilitaet/familienplanung/kontrazeption-in-europa.html?type=98
    PubMedGoogle Scholar
  • 12 BZgA .Verhütungsverhalten Erwachsener. Ergebnisse der Repräsentativbefragung 2007. http://www.bzga.de
    PubMedGoogle Scholar
  • 13 Lader D, Hopkins G. Office for National Statistics. Omnibus Survey Report no. 37. Contraception and Sexual Health 2007 – 2008. 
    PubMedGoogle Scholar
  • 14 http://www.dggg.de/fileadmin/public_docs/Dokumente/Leitlinien/g_02_01_01_empfaengnisverhuetung.pdf
  • 15 http://www.euras-drugsurveillance.info/
  • 16 Gallo M F, Nanda K, Grimes D A et al. 20 µg versus > 20 µg estrogen combined oral contraceptives for contraception.  Cochrane Database of Systematic Reviews. 2008;  (4) CD003989 DOI: 10.1002/14651858.CD003989.pub3
    PubMedGoogle Scholar
  • 17 Grimes D A, Lopez L M, Schulz K F et al. Triphasic versus monophasic oral contraceptives for contraception.  Cochrane Database of Systematic Reviews. 2006;  (3) CD003553 DOI: 10.1002/14651858.CD003553.pub2
    PubMedGoogle Scholar
  • 18 http://www.imshealth.com
  • 19 Jensen J T, Speroff L. Health benefits of oral contraceptives.  Obstet Gynecol Clin North Am. 2000;  27 705-721
    CrossrefPubMedGoogle Scholar
  • 20 Connell E B. Rational use of oral contraceptives in the perimenopausal woman.  J Reprod Med. 1993;  38 (Suppl. 12) 1036-1040
    PubMedGoogle Scholar
  • 21 Kaunitz A M. Oral contraceptive use in perimenopause.  Am J Obstet Gynecol. 2001;  185 (Suppl. 2) S32-S37
    PubMedGoogle Scholar
  • 22 Grigoryan O R, Grodnitskaya E E, Andreeva E N et al. Contraception in perimenopausal women with diabetes mellitus.  Gynecol Endocrinol. 2006;  22 198-206
    CrossrefPubMedGoogle Scholar
  • 23 Visser J, Snel M, van Vliet H A. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.  Cochrane Database Syst Rev. 2006;  (4) CD003990
    PubMedGoogle Scholar
  • 24 http://www.dggg.de/fileadmin/public_docs/Dokumente/Leitlinien/g_02_01_02_kontrazeption_frauen_mit_typ1_typ2diabetes_mit.pdf
  • 25 L'Hermite M, van Pachterbecke C, van Roosendaal E. From oral contraception to hormone replacement therapy: towards a continuum?.  Maturitas. 1988;  Suppl. 1 155-165
    PubMedGoogle Scholar
  • 26 Rudolf K. Kontrazeption in der Prämenopause.  Ther Umsch. 1994;  51 778-783
    PubMedGoogle Scholar
  • 27 Parke S, Makalová D, Ahrendt H J et al. Bleeding patterns and cycle control with a novel four-phasic combined oral contraceptive containing estradiol valerate and Dienogest. 10th Congress of the European Society of Contraception (ESC). 30.4. – 3.5.2008, Prag. 
    PubMedGoogle Scholar
  • 28 Endrikat J, Parke S, Trummer D et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies.  Contraception. 2008;  78 218-225
    CrossrefPubMedGoogle Scholar
  • 29 van den Heuvel M W, van Bragt A J, Alnabawy A K et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive.  Contraception. 2005;  72 168-174
    CrossrefPubMedGoogle Scholar
  • 30 Wiegratz I, Kuhl H. High estrogenic impact on the liver by transdermal contraceptive patch.  Expert Rev Obstet Gynecol. 2007;  2 15-18
    CrossrefPubMedGoogle Scholar
  • 31 Cole J A, Norman H, Doherty M et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.  Obstet Gynecol. 2007;  109 339-346
    CrossrefPubMedGoogle Scholar
  • 32 Lopez L M, Grimes D A, Gallo M F et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception.  Cochrane Database of Systematic Reviews. 2008;  (1) CD003552 DOI: 10.1002/14651858.CD003552.pub2
    PubMedGoogle Scholar
  • 33 Shaaban M M. The Perimenopause and contraception.  Maturitas. 1996;  23 181-192
    CrossrefPubMedGoogle Scholar
  • 34 Buttarelli M, Ghezzi F, Cromi A et al. The use of hormonal contraception in Perimenopause is still a hazard?.  Minerva Gineol. 2001;  53 421-429
    PubMedGoogle Scholar
  • 35 Gebbie A. Contraception in the perimenopause.  J Br Menopause Soc. 2003;  9 123-128
    CrossrefPubMedGoogle Scholar
  • 36 Hardman S M, Gebbie A E. Hormonal contraceptive regimens in the perimenopause.  Maturitas. 2009;  63 204-212
    CrossrefPubMedGoogle Scholar
  • 37 Guilbert E R, Brown J P, Kaunitz A M et al. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health.  Contraception. 2009;  79 167-177
    CrossrefPubMedGoogle Scholar
  • 38 Heinemann L A, Assmann A, DoMinh T et al. Oral progestogen-only contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women.  Eur J Contracept Reprod Health Care. 1999;  4 67-73
    CrossrefPubMedGoogle Scholar
  • 39 Merkl-Feld G S, Imthurn B, Seifert B. Effects of the progestogen-only contraceptive implant Implanon® on cardiovascular risk factors.  Clin Endocrinol (Oxf). 2008;  68 355-360
    PubMedGoogle Scholar
  • 40 WHO collaborative study of cardiovascular disease and steroid hormone contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicentre, case-control study.  Contraception. 1998;  57 315-324
    CrossrefPubMedGoogle Scholar
  • 41 Frederiksen M C. Depot medroxyprogesterone acetate contraception in women with medical problems.  J Reprod Med. 1996;  41 (5 Suppl.) 414-418
    PubMedGoogle Scholar
  • 42 Hudsmith L, Thorne S. Contraception in women with cardiac disease.  Women's Health. 2007;  3 711-717
    PubMedGoogle Scholar
  • 43 Bergendal A, Odlind V, Persson I et al. Limited knowledge on progestogen-only contraception and risk of venous thromboembolism.  Acta Obstet Gynecol Scand. 2009;  88 261-266
    CrossrefPubMedGoogle Scholar
  • 44 Kaunitz A M, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.  Contraception. 2008;  77 67-76
    CrossrefPubMedGoogle Scholar
  • 45 Dutton C, Foldvary-Schaefer N. Contraception in women with epilepsy: pharmacokinetic interactions, contraceptive options, and management.  Int Rev Neurobiol. 2008;  83 113-134
    CrossrefPubMedGoogle Scholar
  • 46 Schwenkhagen A M, Stodieck S R. Which contraception for women with epilepsy?.  Seizure. 2008;  17 145-150
    CrossrefPubMedGoogle Scholar
  • 47 Bhathena R K, Guillebaud J. Contraception for the older woman: an update.  Climacteric. 2006;  9 264-276
    CrossrefPubMedGoogle Scholar
  • 48 Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri- and postmenopausal women.  Contraception. 2007;  75 (6 Suppl.) S155-S160
    CrossrefPubMedGoogle Scholar
  • 49 Kücük T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers.  Clin Exp Obstet Gynecol. 2008;  35 57-60
    PubMedGoogle Scholar
  • 50 Rowlands S. New technologies in contraception.  BJOG. 2009;  116 230-239
    PubMedGoogle Scholar
  • 51 Wildemeersch D, Janssens D, Andrade A. The Femilis LNG-IUS: contraceptive performance–an interim analysis.  Eur J Contracept Reprod Health Care. 2009;  14 103-110
    CrossrefPubMedGoogle Scholar
  • 52 Wildemeersch D, Schacht E, Wildemeersch P. Contraception and treatment in the perimenopausal with a novel “frameless” intrauterine Levonorgestrel-releasing drug delivery system: an extended pilot study.  Contraception. 2005;  66 93-99
    CrossrefPubMedGoogle Scholar
  • 53 Wildemeersch D. New frameless and framed intrauterine devices and systems – an overview.  Contraception. 2007;  75 (6 Suppl.) S82-S92
    CrossrefPubMedGoogle Scholar
  • 54 Andrade A, Wildemeersch D. Menstrual blood loss in women using the frameless FibroPlant LNG-IUS.  Contraception. 2009;  79 134-138
    CrossrefPubMedGoogle Scholar
  • 55 Wildemeersch D, Pylyser K, De Wever N et al. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution.  Maturitas. 2007;  57 205-209
    CrossrefPubMedGoogle Scholar
  • 56 Colls J P. Contraception during perimenopausal years is important issue for patients, clinicians.  Contracept Technol Update. 1984;  5 158-160
    PubMedGoogle Scholar
  • 57 Nelson D B, Sammel M D, Freeman E W et al. Tubal ligation does not affect hormonal changes during the early menopausal transition.  Contraception. 2005;  71 104-110
    CrossrefPubMedGoogle Scholar
  • 58 Sparrow M. Contraception in the perimenopause.  Curr Ther. 1992;  33 43-48
    PubMedGoogle Scholar
  • 59 How to make the switch from OC use to HRT.  Contracept Technol Update. 2000;  21 33
    PubMedGoogle Scholar

PD Dr. Dolores Foth

Uniklinik Köln
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe

Kerpener Straße 34

50931 Köln

Email: dolores.foth@uk-koeln.de